NICE, FRANCE - March 8, 2010 - Iris Pharma, the global specialist in preclinical and clinical ophthalmic research, has recently developed and validated a new animal model that adds itself to its catalogue of animal models: formalin-induced eye discomfort model.
This model, more ethical than the severe eye pain models, allows studying the efficacy of a new product in the treatment of eye discomfort or mild pain in rabbits induced by instillation of formalin. Formalin is the common trade name for formaldehyde, which is a fixative that covalently cross-links proteins in a non-specific fashion.
To propose ever more effective preclinical models, imitating better the aspects of the target pathology and allowing to study with increasing precision the target mechanisms of action, this is the motto of the research department of Iris Pharma. Note that this model is being validated in rats as well.
About Iris Pharma:
Iris Pharma is an independent French CRO that specializes in preclinical and clinical research in the field of ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris Pharma offers its services and expertise in the development of ophthalmic drugs and ocular medical devices to the pharmaceutical industry, biotechnology companies, and research institutes around the world. The company has five main areas of activity: strategic consulting, preclinical studies and services, clinical trials (Phase I to IV and medico-marketing surveys), bioanalytical testing as well as non-GMP preclinical formulation.
Recognized for the rigor and quality of its research, Iris Pharma has been chosen by the European Vision Institute (EVI.CT.SE) as an independent expert in Good Clinical Practice (GCP) for ophthalmic research. Since 1995, Iris Pharma has been recognized as a laboratory that complies with Good Laboratory Practice (GLP).
In May, the company will participate at the Association for Research in Vision and Ophthalmology annual meeting (ARVO) (May 2-6, 2010, Fort Lauderdale, USA - Booth # 400/402) and at the Bio International Convention (May 3-6, 2010, Chicago, USA).
For further information: http://www.iris-pharma.com
